Dr. Davila is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Elm and Carlton St
Buffalo, NY 14263
Education & Training
- Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2006 - 2010
- New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2004 - 2006
- Duke University School of MedicineClass of 2004
- Texas Christian UniversityBS, Biology/Chemistry, Summa Cum Laude, 1991 - 1995
Certifications & Licensure
- FL State Medical License 2015 - 2025
- NY State Medical License 2006 - 2025
- TN State Medical License 2013 - 2015
Awards, Honors, & Recognition
- Young Physician-Scientist Award ASCI Council, 2014
- Amos Medical Faculty Development Program Scholar American Society of Hematology, 2012
- TRiO Achiever Award Texas Christian University, 2011
- Join now to see all
Clinical Trials
- Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 Start of enrollment: 2010 Jan 05
- CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML Start of enrollment: 2021 Jan 14
Publications & Presentations
PubMed
- Synthetic gene circuits drive disease-fighting T cells.Marco L Davila, Renier Brentjens
Science. 2024-12-06 - JAK2/mTOR inhibition fails to prevent acute GVHD despite reduced Th1/Th17 cells: final phase 2 trial results.Joseph Pidala, Shernan G Holtan, Kelly Walton, Jongphil Kim, Biwei Cao
Blood. 2024-11-28 - Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy.Rishika Prasad, Abdur Rehman, Lubna Rehman, Faezeh Darbaniyan, Viktoria Blumenberg
Blood. 2024-10-23
Journal Articles
- CARs move to the Fast LaneDavila ML and Papetrou E, Molecular Therapy, 1/1/2014
- Chimeric Antigen Receptors for the Adoptive T Cell Therapy Of Hematologic MalignanciesDavila, ML, Bouhassira DC, Park JH, Curran KJ, Smith EL, Pegram HJ, and Brentjens R., International Journal of Hematology, 1/1/2014
- Chimeric Antigen Receptor Therapy for Chronic Lymphocytic Leukemia: What are the Challenges?Davila ML, Brentjens R, Hematol Oncol Clin North Am, 1/1/2013
- Join now to see all
Abstracts/Posters
- Human CD83 Targeted Chimeric Antigen Receptor T Cell for the Prevention of Graft Versus Host Disease and Treatment of Myeloid LeukemiaMarco L. Davila, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- The Lymphoma Tumor Microenvironment Influences Toxicity after CD19 CAR T Cell TherapyMarco L. Davila, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Mutation of the CD28 Co-Stimulatory Domain Confers Enhanced CAR T Cell FunctionMarco L. Davila, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- Prediction of CAR T-Related Toxicities in R/R DLBCL Patients Treated with Axicabtagene Ciloleucel Using Point of Care Cytokine Measurements2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Phase 1 Studies Assessing the Safety and Clinical Activity of Multiple Doses of a NKG2D-Based CAR-T Therapy, Cyad-01, in Acute Myeloid Leukemia2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Aged CAR T Cells Exhibit Enhanced Cytotoxicity and Effector Function but Shorter Persistence and Less Memory-like Phenotypes2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
- Cancer Cash Cow: Contrarian Scientists Say Biden's Moonshot Is Largesse for an Already Rich IndustryFebruary 10th, 2023
- Roswell Park Researchers Present New Approach to Understanding Challenging CAR T-cell Toxicities at ASH 2022December 12th, 2022
- Physician-Scientist Marco Davila, MD, PhD, Joins Growing Roswell Park Cellular Therapy ProgramJune 23rd, 2022
- Join now to see all
Grant Support
- The Adoptive Transfer Of Gene-Modified T Cells As A Cell Therapy For LymphomaNational Cancer Institute2010–2011
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: